The House Ways and Means (W&M) Health Subcommittee convened a hearing on the health of the biosimilar market and how increased access to such products can lower prescription drug costs for patients. The following witnesses spoke to the market distortions that impact the biosimilar market, including the tendency for insurers and pharmacy benefit managers (PBMs) to provide preferential formulary placement… (Slifer, April 8, 2025) #Biosimilars, #Prescription Drugs